Adenosine-dependent pulmonary fibrosis in adenosine deaminase-deficient mice.
Pulmonary fibrosis is a common feature of numerous lung disorders, including interstitial lung diseases, asthma, and chronic obstructive pulmonary disease. Despite the prevalence of pulmonary fibrosis, the molecular mechanisms governing inflammatory and fibroproliferative aspects of the disorder are not clear. Adenosine is a purine-signaling nucleoside that is generated in excess during cellular stress and damage. This signaling molecule has been implicated in the regulation of features of chronic lung disease; however, the impact of adenosine on pulmonary fibrosis is not well understood. The goal of this study was to explore the impact of endogenous adenosine elevations on pulmonary fibrosis. To accomplish this, adenosine deaminase (ADA)-deficient mice were treated with various levels of ADA enzyme replacement therapy to regulate endogenous adenosine levels in the lung. Maintaining ADA-deficient mice on low dosages of ADA enzyme therapy led to chronic elevations in lung adenosine levels that were associated with pulmonary inflammation, expression of profibrotic molecules, collagen deposition, and extreme alteration in airway structure. These features could be blocked by preventing elevations in lung adenosine. Furthermore, lowering lung adenosine levels after the establishment of pulmonary fibrosis resulted in a resolution of fibrosis. These findings demonstrate that chronic adenosine elevations are associated with pulmonary fibrosis in ADA-deficient mice and suggest that the adenosine functions as a profibrotic signal in the lung.
Chunn
Janci L
JL
Department of Biochemistry and Molecular Biology, University of Texas Health Science Center at Houston, Medical School, Houston, TX 77030, USA.
Molina
Jose G
JG
Mi
Tiejuan
T
Xia
Yang
Y
Kellems
Rodney E
RE
Blackburn
Michael R
MR
D000241:Adenosine / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000502:physiology*; D000243:Adenosine Deaminase / Q000172:deficiency* / Q000235:genetics* / Q000502:physiology / Q000627:therapeutic use; D000818:Animals; D002908:Chronic Disease; D003094:Collagen / Q000378:metabolism; D004195:Disease Models, Animal; D004306:Dose-Response Relationship, Immunologic; D004334:Drug Administration Schedule; D018836:Inflammation Mediators / Q000037:antagonists & inhibitors / Q000378:metabolism; D008168:Lung / Q000201:enzymology / Q000378:metabolism / Q000473:pathology; D016676:Macrophages, Alveolar / Q000473:pathology; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D011658:Pulmonary Fibrosis / Q000201:enzymology* / Q000235:genetics* / Q000378:metabolism / Q000517:prevention & control; D018047:Receptors, Purinergic P1 / Q000096:biosynthesis / Q000235:genetics
D018836:Inflammation Mediators; D018047:Receptors, Purinergic P1; D003094:Collagen; D000243:Adenosine Deaminase; D000241:Adenosine